PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-89.54%
Both yoy net incomes decline, with VET at -28.32%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
1.22%
Some D&A expansion while VET is negative at -2.65%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-27.27%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
No Data
No Data available this quarter, please select a different quarter.
393.72%
Well above VET's 124.78% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.98%
Growth of 14.98% while VET is zero at 0.00%. Bruce Berkowitz would see a difference in minor WC usage that might affect short-term cash flow if large.
-38.83%
Negative yoy while VET is 21.05%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
37.95%
Operating cash flow growth below 50% of VET's 2702.19%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
-24.36%
Both yoy lines negative, with VET at -328.80%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
24525.00%
Acquisition growth of 24525.00% while VET is zero at 0.00%. Bruce Berkowitz sees a mild outflow that must deliver synergy to justify the difference.
385.71%
Purchases growth of 385.71% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
24.36%
We have some liquidation growth while VET is negative at -100.00%. John Neff notes a short-term liquidity advantage if competitor is holding or restricted.
-284.94%
We reduce yoy other investing while VET is 110.58%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-194.64%
Both yoy lines negative, with VET at -281.93%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-89.47%
Negative yoy issuance while VET is 194.88%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.